These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35641856)

  • 21. Comparative effects of different treatments based on the levonorgestrel intrauterine system in endometrial carcinoma and endometrial hyperplasia patients: a network meta-analysis.
    Tao M; Wu T; Zhou X; Du X; Ling K; Liang Z
    Arch Gynecol Obstet; 2024 Sep; 310(3):1315-1329. PubMed ID: 38980346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
    Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
    J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.
    Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M
    Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system.
    Ercan CM; Duru NK; Sakinci M; Alanbay I; Karasahin KE; Baser I
    Gynecol Endocrinol; 2010 Feb; 26(2):125-8. PubMed ID: 20074021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
    El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
    Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
    Abu Hashim H; Ghayaty E; El Rakhawy M
    Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
    Chen J; Cao D; Yang J; Yu M; Zhou H; Cheng N; Wang J; Zhang Y; Peng P; Shen K
    Int J Gynecol Cancer; 2022 Dec; 32(12):1561-1567. PubMed ID: 36368706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
    Gallos ID; Devey J; Ganesan R; Gupta JK
    Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
    Xu Z; Yang B; Shan W; Liao J; Shao W; Wu P; Zhou S; Ning C; Luo X; Zhu Q; Zhang H; Ma F; Guan J; Chen X
    Gynecol Oncol; 2023 Jul; 174():133-141. PubMed ID: 37182434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
    Zhou H; Cao D; Yang J; Shen K; Lang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman.
    Abu J; Brown L; Ireland D
    Int J Gynecol Cancer; 2006; 16(3):1445-7. PubMed ID: 16803545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
    Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
    J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
    Haoula ZJ; Walker KF; Powell MC
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.